Verinurad
- Generic Name
- Verinurad
- Drug Type
- Small Molecule
- Chemical Formula
- C20H16N2O2S
- CAS Number
- 1352792-74-5
- Unique Ingredient Identifier
- 12WJ62D047
- Background
Verinurad has been used in trials studying the basic science and treatment of Gout, Gout and Hyperuricemia, and Gout and Asymptomatic Hyperuricemia.
Mild, Moderate and Severe Renal Impairment Study
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02219516
Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Phase 2
Completed
- Conditions
- Gout and Hyperuricemia
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 204
- Registration Number
- NCT02078219
- Locations
- 🇯🇵
Research Site, Shinagawa-ku, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath